<p>The Serum Institute of India is set to start trials of Covovax Covid-19 vaccine (Novavax's candidate) on children this month.</p>.<p>The company, one of the world's argest vaccine makers, will conduct trials on children aged 2 to 17 years and the trial will cover about 920 children in two age groups across 10 test sites, according to a <a href="https://www.business-standard.com/topic/serum-institute-of-india" target="_blank">report</a> by <em>Business Standard</em> quoting sources.</p>.<p>The trials for the first group will be conducted for those between 2 and 11 years of age and the second between 12 and 17 years of age.</p>.<p>An expert panel of India's Central Drug Authority on July 27 recommended granting permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covovax on children aged 2 to 17 years with certain conditions late last month.</p>.<p>Union Health Minister Mansukh Mandaviya told BJP MPs that <a href="https://www.deccanherald.com/national/covid-vaccination-for-children-likely-to-start-soon-mandaviya-tells-bjp-mps-1013582.html" target="_blank">Covid vaccination for children is likely to start soon</a>, sources said.</p>.<p>Currently, only those who are 18 or above are eligible for vaccination against the coronavirus. Very soon a vaccine is expected for children and inoculation for them will start, the sources quoted the minister as telling the MPs.</p>.<p>The SII is learnt to have informed that their collaborator, Novavax, Inc., US has already generated a large amount of data in adults in different countries and that the safety, efficacy and immunogenicity data on the Novavax Covid-19 vaccine are very robust which includes a safety database of more than 50,000 adults with data from Australia, South Africa, UK and USA and preliminary safety data in 2248 children.</p>.<p>The SEC on June 30 had recommended against granting permission to SII for conducting phase 2 and 3 trial of Covovax on children aged 2 to 17 years following which the company had submitted a revised study protocol mid-July.</p>.<p>(<em>With inputs from PTI</em>)</p>.<p><strong>Check out DH's latest videos:</strong></p>
<p>The Serum Institute of India is set to start trials of Covovax Covid-19 vaccine (Novavax's candidate) on children this month.</p>.<p>The company, one of the world's argest vaccine makers, will conduct trials on children aged 2 to 17 years and the trial will cover about 920 children in two age groups across 10 test sites, according to a <a href="https://www.business-standard.com/topic/serum-institute-of-india" target="_blank">report</a> by <em>Business Standard</em> quoting sources.</p>.<p>The trials for the first group will be conducted for those between 2 and 11 years of age and the second between 12 and 17 years of age.</p>.<p>An expert panel of India's Central Drug Authority on July 27 recommended granting permission to Serum Institute of India (SII) for conducting phase 2/3 trials of Covovax on children aged 2 to 17 years with certain conditions late last month.</p>.<p>Union Health Minister Mansukh Mandaviya told BJP MPs that <a href="https://www.deccanherald.com/national/covid-vaccination-for-children-likely-to-start-soon-mandaviya-tells-bjp-mps-1013582.html" target="_blank">Covid vaccination for children is likely to start soon</a>, sources said.</p>.<p>Currently, only those who are 18 or above are eligible for vaccination against the coronavirus. Very soon a vaccine is expected for children and inoculation for them will start, the sources quoted the minister as telling the MPs.</p>.<p>The SII is learnt to have informed that their collaborator, Novavax, Inc., US has already generated a large amount of data in adults in different countries and that the safety, efficacy and immunogenicity data on the Novavax Covid-19 vaccine are very robust which includes a safety database of more than 50,000 adults with data from Australia, South Africa, UK and USA and preliminary safety data in 2248 children.</p>.<p>The SEC on June 30 had recommended against granting permission to SII for conducting phase 2 and 3 trial of Covovax on children aged 2 to 17 years following which the company had submitted a revised study protocol mid-July.</p>.<p>(<em>With inputs from PTI</em>)</p>.<p><strong>Check out DH's latest videos:</strong></p>
